Captive Patients, Captive Markets: How Two Corporations Turned Kidney Failure Into a Lifetime Revenue Stream
DaVita and Fresenius together control roughly 70% of all U.S. dialysis clinics, giving them near-total dominion over the 800,000 Americans who depend on kidney treatment to survive. Their business model is not built around curing patients — it is built around keeping them. Understanding how that happened, and who allowed it, is one of the most urgent and least-discussed stories in American healthcare.